All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-04-27T09:34:36.000Z

Significantly higher PFS in R/R CLL with venetoclax-rituximab combo compared to bendamustine

Apr 27, 2018
Share:

Bookmark this article

An article published in the New England Journal of Medicine described a study evaluating the efficacy of the combination of venetoclax and rituximab in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). The venetoclax-rituximab combination was compared to a combination of bendamustine and rituximab in patients randomly assigned to either treatment. The study was published on 22 March 2018, authored by John F Seymour, Director of the Haematology Department at the Peter MacCallum Cancer Centre, Victoria, Australia, and colleagues.

Study Overview

  • Total number of patients involved in the open-label phase III study, N = 389, median age 65 years (22–85)
  • Patients were randomized to receive either venetoclax and rituximab (n = 194) or bendamustine and rituximab (n = 195) that were included in the primary analysis
  • 68 patients completed 2 years of treatment with venetoclax-rituximab and 154 patients completed the scheduled bendamustine-rituximab phase
  • The primary endpoint was investigator-assessed (INV) progression-free survival (PFS)

Key Findings

Efficacy

  • Median follow-up = 23.8 months
  • Venetoclax-rituximab vs bendamustine-rituximab
    • Median PFS = not reached (NR) vs 17 months
    • 2-year INV-assessed PFS = 84.9% (95% CI, 79.1–90.6) vs 3% (95% CI, 28.5–44.0)
      • Hazard ratio (HR) = 0.17 (95% CI, 0.11–0.25)
    • 24-month overall survival (OS) rate = 91.9% vs 6%
      • HR = 0.48 (95% CI, 0.25–0.90)
      • Median OS for both groups were NR
    • Independent review committee-assessed overall response rate (ORR) = 92.3% vs 3%
    • INV-assessed ORR = 93.3% vs 7%
  • 366 patients were tested for minimal residual disease (MRD) from peripheral-blood samples
    • Follow-up showed a higher rate of MRD clearance in venetoclax-rituximab (62.4%) than bendamustine-rituximab (13.3%) at 9 months and (83.5%) vs (23.1%), respectively, at any time during the trial

Safety

  • Most common grade ≥3 adverse events venetoclax-rituximab vs bendamustine-rituximab
    • Neutropenia = 57.7% vs 8%
    • Infections = 17.5% vs 8%
    • Anemia = 10.8% vs 8%

The authors found that there was significantly higher PFS for R/R CLL patients with venetoclax-rituximab combination than with bendamustine-rituximab. They noted that the difference in response rates assessed by investigators and an independent review committee was due to differing interpretations of residual adenopathy on computed tomographic scans. No new safety signals emerged. The authors concluded that durability of responses would need to be determined to further assess the potential of venetoclax-rituximab therapy.

  1. Seymour JF. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. The New England Journal of Medicine. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox